As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.
Union therapeutics is also developing the drug for treatment of atopic dermatitis and hidradenitis suppurativa.
Patients with psoriasis were more likely to receive emergency food from churches, food banks, or soup kitchens.
Boni E. Elewski, MD, shares her management pearls of how to treat difficult nail psoriasis and onychomycosis at the 2023 Winter Clinical Hawaii Dermatology Conference.
An expert dermatologist reviews generalized pustular psoriasis in 2 patients and how he would approach treatment and management.
Linda Stein Gold, MD, and Jennifer Soung, MD, discuss available nonsteroidal treatment options for plaque psoriasis in this DermView series recap.
JNJ-2113 met primary endpoints in the FRONTIER 1 clinical trial.
What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.
It has been hypothesized that some lipid-lowering drugs are disease-modifying for psoriasis, and the use of lipid-lowering drugs in the management of psoriasis symptoms is currently being explored.
Oral vitamin D supplementation does not appear to have an effect on disease severity for those with low 25-hydroxyvitamin D (25[OH]D) levels.
The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.
As many as 1 in 5 patients with psoriasis experience depression as a comorbidity.
Researchers examined the disease while going beyond current diagnostic tools.
The IL-23p19 inhibitor demonstrated long-term efficacy and safety.
In one-third of cases of psoriasis, disease onset occurs in the first or second decade of life, although it may not be diagnosed until the patient has reached adulthood.
Melodie Young, MSN, ANP-c, shares pearls on why prioritizing skin checks during Psoriasis Action Month in August is critical.
The American Academy of Dermatology’s new project uses AI to take treatment for individuals with generalized pustular psoriasis to the next level.
Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.
Janssen Pharmaceutical Companies announced its oral treatment for moderate to severe plaque psoriasis will be taken to Phase 3 clinical trials.
Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.
Additional patients will be enrolled in the phase 2a study after a clear biological signal was demonstrated in initial participants.
In the PERSIST study, improvements were sustained through week 104.
In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.
Investigators noted that there was not a marked increase, however, in keratinocyte skin carcinomas.
The findings highlight new data on AXL expression in inflammatory diseases.
In the cohort trial, 85% of patients showed an improvement of more than 50 on PASI.
As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.
The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.
There may be delays in diagnosis and treatment of psoriasis in patients with darker skin tones due to the clinical presentation variations and less visible erythema.
FDA action is no longer expected in Q3 of 2023.
Researchers explored the relationship between psoriasis severity and its link to coronary microvascular dysfunction in the largest such study to date.
The September 2023 issue of Dermatology Times featured a spotlight on psoriasis research, advances, and treatment options in patients with skin of color. Learn more about the topics covered in each spotlight article.
The approval provides pediatric patients with a steroid-free topical therapy.
Protagonist Therapeutics has just announced the company's eligibility to receive $60 million of milestone payments for JNJ-2113 to enter into clinical development programs led by Janssen.
Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.
Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.
Black and male patients exhibited a higher prevalence of palmoplantar psoriasis when compared with White patients.
Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.
The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.
PASI scores were significantly correlated with sleep quality, duration, and disturbances.
Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.